Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (3458)	4/18/2001 10:52:37 PM
From: Jibacoa	Respond to of 52153

Some news on LEXG today besides yesterday's news with BMY: THE WOODLANDS, Texas, April 17 /PRNewswire/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - news) announced today that it has delivered to Bristol-Myers Squibb Company (NYSE: BMY - news) the second installment of the LexVision database containing in vivo mammalian gene function information for potential new drug targets. THE WOODLANDS, Texas, April 18 /PRNewswire/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - news) is announcing at its investor/analyst conference today a major scale-up of its gene knockout and in vivo functional analysis programs to determine the function of 5,000 genes over five years for the discovery of new disease targets. Lexicon is focusing its large-scale gene function discovery process on those proteins encoded by pharmaceutically valuable gene families. These include genes that encode medically important proteins such as receptors, ion channels, key enzymes, and secreted proteins. ``Lexicon is amassing the world's largest gene knockout infrastructure, and today we are revealing the magnitude of our capabilities,'' said Arthur T. Sands, M.D., Ph.D., President and Chief Executive Officer of Lexicon. ``It is believed that the human genome encodes as many as 5,000 novel drug targets. By contrast, the entire pharmaceutical industry today operates on fewer than 500 targets. With the completion of our genome discovery pharmaceutical center at the end of 2001, we are scaling up our gene knockout process to determine the in vivo functions of 5,000 of the most promising genes for pharmaceutical discovery over five years.'' The stock still has to get over that resistance at 8.50<g> siliconinvestor.com After that it should test the March 7 H at 10.31 siliconinvestor.com Bernard